Skip to main content
. 2016 Apr 20;5(1):31–34. doi: 10.3892/mco.2016.864

Figure 2.

Figure 2.

Clinical course of the patient in case 2. GO, gemtuzumab ozogamicin; PT, prothrombin time; WBC, white blood cell count; PLT, platelets; rTM, recombinant human soluble thrombomodulin; APTT, activated partial thromboplastin time; FDP, fibrin degradation product; PCR, polymerase chain reaction; PML, promyelocytic leukemia; RAR, retinoic acid receptor; FISH, fluorescent in situ hybridization.